URGN - ユ―ロジェン・ファ―マ (UroGen Pharma Ltd.)

URGNのニュース

   Urogen Pharma Ltd (NASDAQ:URGN) Given Consensus Rating of “Hold” by Analysts  2020/10/25 00:28:41 US Banking News
Urogen Pharma Ltd (NASDAQ:URGN) has received an average recommendation of “Buy” from the nine research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective […]
   Urogen Pharma Ltd (NASDAQ:URGN) Receives Average Rating of “Hold” from Analysts  2020/10/24 22:28:47 Daily Political
Shares of Urogen Pharma Ltd (NASDAQ:URGN) have received a consensus rating of “Buy” from the nine analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating on the company. The average 1-year price […]
   UroGen Pharma : Reports Second Quarter 2020 Financial Results and Recent Corporate Developments | MarketScreener  2020/08/10 12:04:04 MarketScreener
Received U.S. FDA Approval of Jelmyto®, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer Successfully Commenced Launch of Jelmyto on June 1st… | August 10, 2020
   UroGen Pharma to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020  2020/08/03 12:00:00 Business Wire
UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases
   UroGen Pharma to Present at Jefferies Virtual Healthcare Conference  2020/06/01 12:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that Liz Barrett, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020, at 3:30 PM Eastern Time. A live audio webcast of the event will be available on the Investors section of UroGen's website, www.urogen
   UroGen Pharma : Reports Second Quarter 2020 Financial Results and Recent Corporate Developments | MarketScreener  2020/08/10 12:04:04 MarketScreener
Received U.S. FDA Approval of Jelmyto®, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer Successfully Commenced Launch of Jelmyto on June 1st… | August 10, 2020
   UroGen Pharma to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020  2020/08/03 12:00:00 Business Wire
UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases
   UroGen Pharma to Present at Jefferies Virtual Healthcare Conference  2020/06/01 12:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that Liz Barrett, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020, at 3:30 PM Eastern Time. A live audio webcast of the event will be available on the Investors section of UroGen's website, www.urogen
   UroGen Pharma Reports First Quarter 2020 Financial Results and Recent Corporate Developments  2020/05/07 12:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced financial results for the first quarter ended March 31, 2020 and provided an overview of the Company’s recent developments. “The first quarter of 2020 was marked by flawless execution by our team as we prepared for the landmark FDA approval of Jelmyto, the first and only non-
   UroGen Pharma to Report First Quarter 2020 Financial Results On Thursday, May 7, 2020  2020/05/01 12:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will report first quarter 2020 financial results on Thursday, May 7, 2020, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30AM Eastern Time. Audio Webcast The webcast will be made
   UroGen Pharma to Present at Jefferies Virtual Healthcare Conference  2020/06/01 12:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that Liz Barrett, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020, at 3:30 PM Eastern Time. A live audio webcast of the event will be available on the Investors section of UroGen's website, www.urogen
   UroGen Pharma Reports First Quarter 2020 Financial Results and Recent Corporate Developments  2020/05/07 12:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced financial results for the first quarter ended March 31, 2020 and provided an overview of the Company’s recent developments. “The first quarter of 2020 was marked by flawless execution by our team as we prepared for the landmark FDA approval of Jelmyto, the first and only non-
   UroGen Pharma to Report First Quarter 2020 Financial Results On Thursday, May 7, 2020  2020/05/01 12:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will report first quarter 2020 financial results on Thursday, May 7, 2020, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30AM Eastern Time. Audio Webcast The webcast will be made
   The Week Ahead In Biotech (April 19-25): Eli Lilly, Biogen Earnings On Tap, Sanofi Awaits FDA Decision  2020/04/19 21:22:22 Benzinga Feeds
Biotech stocks staged a nice recovery along with the broader markets in the week ended April 17. Apart from the broader market sentiment, big moves in biopharma companies such as Johnson & Johnson (NYSE: JNJ ) and Gilead Sciences, Inc. (NASDAQ: GILD ) also supported sentiment. The former reported strongly quarterly results and the latter benefited from reports of positive efficacy data on its COVID-19 treatment candidate remdesivir. Urogen Pharma Ltd (NASDAQ: URGN ) gained approval for its low-grade bladder cancer drug. News flow concerning the … Full story available on Benzinga.com
   The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant  2020/04/16 12:09:13 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 15.) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) C alithera Biosciences Inc (NASDAQ: CALA ) (provided an update on the impact of COVID-19 on its ongoing clinical trials) Eli Lilly And Co (NYSE: LLY ) Keros Therapeutics Inc (NASDAQ: KROS ) (went public April 8) Masimo Corporation (NASDAQ: MASI ) Moderna Inc (NASDAQ: MRNA (analysts hiked price targets for the shares following the company's Virtual Vaccines Day) Pluristem Therapeutics Inc. (NASDAQ: PSTI ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Down In The Dumps (Biotech stocks that hit 52-week lows April 15.) Akorn, Inc. (NASDAQ: AKRX ) AxoGen, Inc Common Stock (NASDAQ: AXGN ) TherapeuticsMD Inc (NASDAQ: TXMD ) Vaccinex Inc (NASDAQ: VCNX ) Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter .

calendar